亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Novel Heart Attack Therapy: Caspase Inhibition Prior to Repurfusion

详细技术说明
OPPORTUNITY Preventing heart muscle death (infarction) during a heart attack is an important goal of treatment. To this end, patients typically receive platelet inhibitors and early opening of the thrombosed artery (reperfusion), both of which aim to reduce heart muscle loss. This treatment has lowered, but not eliminated, mortality and morbidity in these patients. Recent work in this field, including clinical trials, focused on “conditioning” interventions have failed to improve outcomes, presumably because they protect by the same mechanism as the platelet inhibitors. Therefore, there is still an unmet need for a therapy that adds to the protective effect of platelet inhibitors, rather than simply duplicating it. BREAKTHROUGH IN TREATMENT OF MYOCARDIAL INFARCTIONResearchers at the University of South Alabama discovered that caspases, key enzymes in inflammation, also contribute to death of heart muscle during a simulated heart attack. In rat hearts, inhibiting a particular caspase with a highly selective caspase inhibitor greatly reduces infarct by a magnitude similar to that reported when using platelet inhibitors (standard of care). In rats receiving a combination treatment of both a platelet inhibitor (standard of care) and the caspase inhibitor administered prior to reperfusion, an additive reduction in infarct size is observed. This implicates caspases as a causative component of cell death in myocardial infarction, against which the platelet inhibitors do not protect. Thus, we believe that the use of the highly specific caspase inhibitor offers additional clinical benefit to patients receiving treatment for acute myocardial infarction. COMPETITIVE ADVANTAGES•  Novel use of existing compound•  Reduction of infarct size when used in combination with a platelet inhibitor•  Highest degree of cardioprotection observed in a rodent myocardial infarction model•  Treatment effective when initiated 60-minutes after coronary occlusion•  Infarct size smaller and contractile function of the heart preserved following treatment INTELLECTUAL PROPERTY STATUSPatent filed Download a PDF version of the description
*Abstract
None
*Principal Investigation

Name: Jonathon Audia, Associate Professor

Department: Microbiology and Immunology


Name: James Downey

Department: Physiology


Name: Diego Alvarez, Associate Professor

Department: Pharmacology


Name: Michael Cohen, Professor

Department: Physiology

国家/地区
美国

欲了解更多信息,请点击 这里
移动设备